June 5, 2020 / 5:31 AM / a month ago

BRIEF-UCB Acquires Engage Therapeutics

June 5 (Reuters) - Ucb SA:

* UCB ACQUIRES ENGAGE THERAPEUTICS: STACCATO ALPRAZOLAM

* ACQUISITION DOES NOT IMPACT UCB’S 2020 FINANCIAL OUTLOOK

* INITIAL UPFRONT PAYMENT OF US$ 125 MILLION AND FURTHER POTENTIAL MILESTONE PAYMENTS OF UP TO US$ 145 MILLION, TOTAL POTENTIAL CONSIDERATION OF UP TO US$ 270 MILLION

* UCB HAS ALSO ENTERED INTO AN UPDATED LICENSE AND RELATED COMMERCIAL SUPPLY AGREEMENT WITH ALEXZA

* STACCATO ALPRAZOLAM COULD BE POTENTIAL SOLUTION FOR 20-30% OF EPILEPSY PATIENTS Source text : bit.ly/3cAQYCI Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below